On November 2, 2026, Syndax Pharmaceuticals, Inc. announced a leadership transition and reported its financial results for the third quarter ended September 30, 2026. The company disclosed that Keith A. Goldan will retire as Chief Financial Officer, principal accounting and financial officer, and treasurer effective November 9, 2026. Mr. Goldan will continue as an advisor for an interim period following his retirement.
Mr. Goldan will be succeeded by Aaron A. Ondrey, who will assume the role of Chief Financial Officer, principal accounting and financial officer, and treasurer effective November 9, 2026. Mr. Ondrey previously served as Chief Financial Officer of Beren Therapeutics, a private company, since September 2025. Prior to that, he held CFO roles at Rocket Pharmaceuticals and Mirati Therapeutics, and held financial leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.
Syndax also disclosed the terms of Mr. Ondrey’s employment agreement. He will receive an annual base salary of $543,000 and an annual target bonus equal to 45% of his base salary. In connection with his appointment, he was granted an option to purchase 270,000 shares of the company’s common stock, with vesting scheduled over four years. The agreement outlines severance benefits in the event of termination without cause or termination for good reason, including accelerated vesting of equity awards.
In its financial results for the third quarter of 2026, Syndax reported total revenue of $83.3 million. This figure consists of $60.7 million in net revenue from Revuforj (revumenib) and $22.6 million in collaboration revenue from Niktimvo (axatilimab-csfr). The company reported cash, cash equivalents, and short- and long-term investments of $551.1 million as of September 30, 2026.
